Viking has long been viewed as a takeover target, given the positive data from early VK2735 trials. The company’s most recent ...

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...

ABB to unveil the future technologies at Society for Laboratory Automation and Screening conference January 20, 2025 by David ...

The following is a summary of “Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

With weight loss drugs like metformin and Ozempic gaining popularity, it’s essential to understand how they compare. So we ...

In some cases slowing the rate of titration or reducing the dose may also be considered. It would be prudent not to add other vasodilators such as calcium antagonists, nitrates, or other ...

Continuous positive airway pressure (CPAP) therapy, which is the most common treatment for obstructive sleep apnea (OSA), may ...

The findings were published online in the CHEST Journal on December 30, 2024.

Cantex Mine Development Corp. (TSXV: CD) (OTCQB: CTXDF) (the "Company") is pleased to provide an update on its ...

Ascletis announces positive results from US phase Ia SAD study of small molecule oral GLP-1R agonist ASC30 in patients with obesity: Hong Kong, China Wednesday, January 22, 2025, ...

Cantex Mine Development Corp. (TSXV: CD) (OTCQB: CTXDF) (the "Company") is pleased to provide an update on its 100-percent-owned 14,07 ...